Currently, there are 217.98M common shares owned by the public and among those 180.17M shares have been available to trade.
The company’s stock has a 5-day price change of -12.69% and 14.86% over the past three months. OSCR shares are trading -8.70% year to date (YTD), with the 12-month market performance up to 6.99% higher. It has a 12-month low price of $11.20 and touched a high of $23.79 over the same period. OSCR has an average intraday trading volume of 15.45 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -18.80%, -10.74%, and -7.35% respectively.
Institutional ownership of Oscar Health Inc (NYSE: OSCR) shares accounts for 61.97% of the company’s 217.98M shares outstanding.
It has a market capitalization of $3.66B and a beta (3y monthly) value of 1.89. The stock’s trailing 12-month PE ratio is 51.62, while the earnings-per-share (ttm) stands at $0.28. The company has a PEG of 0.36 and the debt-to-equity ratio at 0.22. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.93% over the week and 7.99% over the month.
Analysts forecast that Oscar Health Inc (OSCR) will achieve an EPS of 0.42 for the current quarter, -0.14 for the next quarter and 1.19 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.39 while analysts give the company a high EPS estimate of 0.39. Comparatively, EPS for the current quarter was 0.2 a year ago. Earnings per share for the fiscal year are expected to increase by 232.58%, and 92.90% over the next financial year.
Looking at the support for the OSCR, a number of firms have released research notes about the stock. Wells Fargo stated their Underweight rating for the stock in a research note on July 11, 2025, with the firm’s price target at $10. Barclays coverage for the Oscar Health Inc (OSCR) stock in a research note released on July 02, 2025 offered a Underweight rating with a price target of $17. Raymond James was of a view on June 24, 2025 that the stock is Mkt Perform, while Wells Fargo gave the stock Equal Weight rating on March 13, 2025, issuing a price target of $20- $16. Jefferies on their part issued Underperform rating on December 10, 2024.
